Evidence map›Paper›PMID 38349142›Full record

ArticlemBio2024

Prior dengue virus serotype 3 infection modulates subsequent plasmablast responses to Zika virus infection in rhesus macaques.

Tulika Singh, Itzayana G Miller, Sravani Venkatayogi, Helen Webster, Holly J Heimsath, Josh A Eudailey, Dawn M Dudley, Amit Kumar, Riley J Mangan, Amelia Thein and 9 more

Open access · goldAbstract read
In one paragraph

Article in mBio, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.7field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Advances in Single-Cell Sequencing for Infectious Diseases: Progress and Perspectives.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
  2. Review
  3. Reconciling heterogeneous dengue virus infection risk estimates from different study designs.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 4 institutions in 1 country.

Tulika SinghHuman Vaccine Institute, School of Medicine, Duke University, Durham, North Carolina, USA.ORCID 0000-0002-7416-7861
Itzayana G MillerDepartment of Pediatrics, Weill Cornell Medicine, New York, USA.
Sravani VenkatayogiHuman Vaccine Institute, School of Medicine, Duke University, Durham, North Carolina, USA.
Helen WebsterHuman Vaccine Institute, School of Medicine, Duke University, Durham, North Carolina, USA.
Holly J HeimsathHuman Vaccine Institute, School of Medicine, Duke University, Durham, North Carolina, USA.
Josh A EudaileyHuman Vaccine Institute, School of Medicine, Duke University, Durham, North Carolina, USA.
Dawn M DudleyDepartment of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Amit KumarHuman Vaccine Institute, School of Medicine, Duke University, Durham, North Carolina, USA.
Riley J ManganHuman Vaccine Institute, School of Medicine, Duke University, Durham, North Carolina, USA.
Amelia TheinDepartment of Pediatrics, Weill Cornell Medicine, New York, USA.
Matthew T AliotaDepartment of Veterinary and Biomedical Sciences, University of Minnesota, Twin Cities, St. Paul, Minnesota, USA.ORCID 0000-0002-6902-9149
Christina M NewmanDepartment of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Mariel S MohnsDepartment of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Meghan E BreitbachDepartment of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Madison BerryHuman Vaccine Institute, School of Medicine, Duke University, Durham, North Carolina, USA.
Thomas C FriedrichDepartment of Pathobiological Sciences, University of Wisconsin-Madison, Madison, Wisconsin, USA.ORCID 0000-0001-9831-6895
Kevin WieheHuman Vaccine Institute, School of Medicine, Duke University, Durham, North Carolina, USA.
David H O'ConnorDepartment of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Sallie R PermarHuman Vaccine Institute, School of Medicine, Duke University, Durham, North Carolina, USA.ORCID 0000-0003-1438-4554
Duke University · USUniversity of Wisconsin–Madison · USCornell University · USUniversity of Minnesota · US

Funding

WNPRC Supplemental Request for Nonhuman Primate Enclosures to Equip HIV/AIDS-Related Research FacilitiesP51OD011106 · OD · UNIVERSITY OF WISCONSIN-MADISON · PI Dorota A. Grejner-Brzezinska · 2012 to 2026
$150.7M
Nonhuman Primate Reagent ResourceU24AI126683 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI Diogo Magnani · 2016 to 2026
$20.1M
Zika virus pathophysiology during pregnancyP01AI132132 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI O'CONNOR, DAVID H. · 2018 to 2022
$10.2M
Viral Oncology Training GrantT32CA009111 · NCI · DUKE UNIVERSITY · PI LUFTIG, MICAH A. · 1985 to 2023
$8.9M
Maternal immune protection against congenital CMV infectionDP2HD075699 · NICHD · DUKE UNIVERSITY · PI PERMAR, SALLIE R. · 2012 to 2017
$2.8M
NCI NIH HHS T32 CA009111NIAID NIH HHS P01 AI132132NIAID NIH HHS U24 AI126683NICHD NIH HHS DP2 HD075699NIH HHS P51 OD011106
6 · The paper itself

Abstract

Immunodominant and highly conserved flavivirus envelope proteins can trigger cross-reactive IgG antibodies against related flaviviruses, which shapes subsequent protection or disease severity. This study examined how prior dengue serotype 3 (DENV-3) infection affects subsequent Zika virus (ZIKV) plasmablast responses in rhesus macaques ( IMPORTANCE: The Zika virus epidemic of 2015-2016 in the Americas revealed that this mosquito-transmitted virus could be congenitally transmitted during pregnancy and cause birth defects in newborns. Currently, there are no interventions to mitigate this disease and Zika virus is likely to re-emerge. Understanding how protective antibody responses are generated against Zika virus can help in the development of a safe and effective vaccine. One main challenge is that Zika virus co-circulates with related viruses like dengue, such that prior exposure to one can generate cross-reactive antibodies against the other which may enhance infection and disease from the second virus. In this study, we sought to understand how prior dengue virus infection impacts subsequent immunity to Zika virus by single-cell sequencing of antibody producing cells in a second Zika virus infection. Identifying specific qualities of Zika virus immunity that are modulated by prior dengue virus immunity will enable optimal immunization strategies.

Indexed as

DengueDengue VirusFlavivirusZika VirusZika Virus InfectionAnimalsAntibodies, NeutralizingAntibodies, ViralCross ReactionsImmunoglobulin GMacaca mulattaSerogroupAntibodies, NeutralizingAntibodies, ViralImmunoglobulin GB celldengue virusneutralizing antibodiesplasmablastZika virus

Identifiers

PMID38349142
PMCPMC10936420
OpenAlexW4391786368

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.